COVID-19-associated neutrophilia: Difference between revisions
Jump to navigation
Jump to search
Fausatadogba (talk | contribs) No edit summary |
|||
| Line 9: | Line 9: | ||
==Overview== | ==Overview== | ||
[[Coronavirus]] disease 2019 (COVID-19) has been considered as a global [[pandemic]] since its first emergence in Wuhan,China.On March 12, 2020, the [[World Health Organization]] declared the COVID-19 outbreak a pandemic | [[Coronavirus]] disease 2019 (COVID-19) has been considered as a global [[pandemic]] since its first emergence in Wuhan,China.On March 12, 2020, the [[World Health Organization]] declared the COVID-19 outbreak a pandemic.There is no established system for the classification regarding COVID-19 associated [[neutrophilia]].Research suggests COVID-19 associated neutrophilia could be the cause of the severe symptoms of COVID-19, including [[Acute respiratory distress syndrome|Acute Respiratory Distress Syndrome]] (ARDS). It can be linked to the [[Neutrophil]] Extracellular Traps (NETs). [[Acute respiratory distress syndrome|Acute Respiratory Distress Syndrome]] (ARDS), [[pulmonary inflammation]], thick mucus secretions in the airways, extensive lung damage, and blood clots are suggested to be as a result of the action of [[Neutrophils]]. When [[Neutrophil|neutrophils]] detect pathogens, they can expel their DNA in a web laced with toxic enzymes (called a NET- Neutrophil Extracellular Trap) to attack them.These NETs capture and digest the unwanted [[pathogen]] but in cases of ARDS (Covid-19 manifestation) they cause damage to the lungs and other organs. People of any age with certain underlying medical conditions are at increased risk for severe illness from COVID-19.Recent studies have shown the association of a high Neutrophil-to-lymphocyte ratio (NLR) to severe forms of COVID-19 disease. | ||
==Historical Perspective== | ==Historical Perspective== | ||
| Line 19: | Line 19: | ||
==Classification== | ==Classification== | ||
There is no established system for the classification regarding COVID-19 associated [[neutrophilia]]. | There is no established system for the classification regarding COVID-19 associated [[neutrophilia]]. | ||
==Pathophysiology== | |||
*Study suggests COVID-19 associated neutrophilia could be the cause of the severe symptoms of COVID-19, including [[Acute respiratory distress syndrome|Acute Respiratory Distress Syndrome]] (ARDS). It can be linked to the '''Neutrophil Extracellular Traps (NETs)'''. | |||
*[[Acute respiratory distress syndrome|Acute Respiratory Distress Syndrome]] (ARDS), [[pulmonary inflammation]], thick mucus secretions in the airways, extensive lung damage, and blood clots are suggested to be as a result of the action of [[Neutrophils]]. When [[Neutrophil|neutrophils]] detect pathogens, they can expel their DNA in a web laced with toxic enzymes (called a NET- Neutrophil Extracellular Trap) to attack them. | |||
*These NETs capture and digest the unwanted [[pathogen]] but in cases of ARDS (Covid-19 manifestation) they cause damage to the lungs and other organs. <ref name="urlSevere COVID-19 symptoms may be caused by overactive neutrophils">{{cite web |url=https://www.drugtargetreview.com/news/60212/severe-covid-19-symptoms-may-be-caused-by-overactive-neutrophils/ |title=Severe COVID-19 symptoms may be caused by overactive neutrophils |format= |work= |accessdate=}}</ref> | |||
==Causes== | ==Causes== | ||
The SARS-CoV-2 [[COVID-19]] viral infection is the known cause of neutrophilia associated disease in infected patients. | |||
==Differentiating COVID-19 related Neutrophilia from other Diseases== | ==Differentiating COVID-19 related Neutrophilia from other Diseases== | ||
| Line 59: | Line 63: | ||
==Diagnosis== | ==Diagnosis== | ||
===Diagnostic study of Choice === | ===Diagnostic study of Choice === | ||
* | *Peripheral white blood cell count on a CBC with differential test<ref name="urlNeutrophilia: Overview, Causes, Development of Neutrophils">{{cite web |url=https://emedicine.medscape.com/article/208576-overview#a7 |title=Neutrophilia: Overview, Causes, Development of Neutrophils |format= |work= |accessdate=}}</ref> | ||
*Neutrophil-lymphocyte ratio | |||
*C-reactive protein | *C-reactive protein | ||
*Erythrocyte sedimentation rate | *Erythrocyte sedimentation rate | ||
| Line 77: | Line 82: | ||
*[[Diarrhea]] | *[[Diarrhea]] | ||
===Physical Examination=== | |||
*There are no physical findings associated with neutrophilia. | |||
===Laboratory findings=== | |||
==Neutrophilia as an indicator for severe disease== | ==Neutrophilia as an indicator for severe disease== | ||
*Recent studies have shown the association of a high Neutrophil-to-lymphocyte ratio (NLR) to severe forms of COVID-19 disease. | *Recent studies have shown the association of a high Neutrophil-to-lymphocyte ratio (NLR) to severe forms of COVID-19 disease. | ||
*NLR >4 on admission has been linked to ICU admission. | *NLR >4 on admission has been linked to ICU admission. | ||
*COVID-19 patients with severe disease presentation had a higher NLR on admission compared to patients with a milder COVID-19 disease presentation.<ref name="CicculloBorghetti2020">{{cite journal|last1=Ciccullo|first1=Arturo|last2=Borghetti|first2=Alberto|last3=Zileri Dal Verme|first3=Lorenzo|last4=Tosoni|first4=Alberto|last5=Lombardi|first5=Francesca|last6=Garcovich|first6=Matteo|last7=Biscetti|first7=Federico|last8=Montalto|first8=Massimo|last9=Cauda|first9=Roberto|last10=Di Giambenedetto|first10=Simona|title=Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line|journal=International Journal of Antimicrobial Agents|year=2020|pages=106017|issn=09248579|doi=10.1016/j.ijantimicag.2020.106017}}</ref> | *COVID-19 patients with severe disease presentation had a higher NLR on admission compared to patients with a milder COVID-19 disease presentation.<ref name="CicculloBorghetti2020">{{cite journal|last1=Ciccullo|first1=Arturo|last2=Borghetti|first2=Alberto|last3=Zileri Dal Verme|first3=Lorenzo|last4=Tosoni|first4=Alberto|last5=Lombardi|first5=Francesca|last6=Garcovich|first6=Matteo|last7=Biscetti|first7=Federico|last8=Montalto|first8=Massimo|last9=Cauda|first9=Roberto|last10=Di Giambenedetto|first10=Simona|title=Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line|journal=International Journal of Antimicrobial Agents|year=2020|pages=106017|issn=09248579|doi=10.1016/j.ijantimicag.2020.106017}}</ref> | ||
===Electrocardiogram== | |||
There are no ECG findings associated with [[COVID-19]] associated neutrophilia | |||
===X-ray=== | |||
There are no X-ray findings associated with [[COVID-19]] associated neutrophilia. | |||
===Echocardiography or Ultrasound=== | |||
There are no echocardiography or ultrasound findings associated with [[COVID-19]] associated neutrophilia. | |||
===CT Scan=== | |||
There are no CT scan findings associated with [[COVID-19]] associated neutrophilia. | |||
===MRI=== | |||
There are no MRI findings associated with [[COVID-19]] associated neutrophilia. | |||
===Other imaging findings=== | |||
There are no other imaging findings associated with [[COVID-19]] associated neutrophilia. | |||
===Other Diagnostic studies=== | |||
*Bone marrow biopsy, although not recommended may be helpful if there is suspicion of other disorders that can cause neutrophilia , but there is not enough evidence to support bone marrow biopsy in COVID-19 patients. | |||
==Treatment== | |||
===Medical therapy=== | |||
Immune-Based Therapy: | |||
*There are insufficient data to recommend either for or against the use of COVID-19 convalescent plasma or SARS-CoV-2 immune globulins for the treatment of [[COVID-19]]. | |||
The COVID-19 Treatment Guidelines Panel (the Panel) recommends against the use of non-SARS-CoV-2-specific intravenous immune globulin (IVIG) for the treatment of COVID-19, except in the context of a clinical trial. This should not preclude the use of IVIG when it is otherwise indicated for the treatment of complications that arise during the course of [[COVID-19]].<ref name="urlImmune-Based Therapy | Coronavirus Disease COVID-19">{{cite web |url=https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/ |title=Immune-Based Therapy | Coronavirus Disease COVID-19 |format= |work= |accessdate=}}</ref> | |||
*There are insufficient data to recommend either for or against the use of the following agents for the treatment of [[COVID-19]]: | |||
**Interleukin-1 inhibitors (e.g., anakinra) | |||
**Interleukin-6 inhibitors (e.g., sarilumab, siltuximab, tocilizumab) | |||
Except in the context of a clinical trial, the Panel recommends against the use of other immunomodulators, such as: | |||
Interferons, because of the lack of efficacy in treatment of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) and toxicity. | |||
Janus kinase inhibitors (e.g., baricitinib), because of their broad immunosuppressive effect.<ref name="urlImmune-Based Therapy | Coronavirus Disease COVID-19">{{cite web |url=https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/ |title=Immune-Based Therapy | Coronavirus Disease COVID-19 |format= |work= |accessdate=}}</ref> | |||
==References== | ==References== | ||
Revision as of 22:29, 3 July 2020
For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Oluwabusola Fausat Adogba, MD
Synonyms and keywords:
Overview
Coronavirus disease 2019 (COVID-19) has been considered as a global pandemic since its first emergence in Wuhan,China.On March 12, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic.There is no established system for the classification regarding COVID-19 associated neutrophilia.Research suggests COVID-19 associated neutrophilia could be the cause of the severe symptoms of COVID-19, including Acute Respiratory Distress Syndrome (ARDS). It can be linked to the Neutrophil Extracellular Traps (NETs). Acute Respiratory Distress Syndrome (ARDS), pulmonary inflammation, thick mucus secretions in the airways, extensive lung damage, and blood clots are suggested to be as a result of the action of Neutrophils. When neutrophils detect pathogens, they can expel their DNA in a web laced with toxic enzymes (called a NET- Neutrophil Extracellular Trap) to attack them.These NETs capture and digest the unwanted pathogen but in cases of ARDS (Covid-19 manifestation) they cause damage to the lungs and other organs. People of any age with certain underlying medical conditions are at increased risk for severe illness from COVID-19.Recent studies have shown the association of a high Neutrophil-to-lymphocyte ratio (NLR) to severe forms of COVID-19 disease.
Historical Perspective
- Coronavirus disease 2019 (COVID-19) has been considered as a global pandemic since its first emergence in Wuhan,China.[1]
- On March 12, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic.
Classification
There is no established system for the classification regarding COVID-19 associated neutrophilia.
Pathophysiology
- Study suggests COVID-19 associated neutrophilia could be the cause of the severe symptoms of COVID-19, including Acute Respiratory Distress Syndrome (ARDS). It can be linked to the Neutrophil Extracellular Traps (NETs).
- Acute Respiratory Distress Syndrome (ARDS), pulmonary inflammation, thick mucus secretions in the airways, extensive lung damage, and blood clots are suggested to be as a result of the action of Neutrophils. When neutrophils detect pathogens, they can expel their DNA in a web laced with toxic enzymes (called a NET- Neutrophil Extracellular Trap) to attack them.
- These NETs capture and digest the unwanted pathogen but in cases of ARDS (Covid-19 manifestation) they cause damage to the lungs and other organs. [2]
Causes
The SARS-CoV-2 COVID-19 viral infection is the known cause of neutrophilia associated disease in infected patients.
COVID-19 related Neutrophilia starts acutely in the course of the disease, with other manifestations of the disease. Neutrophilia can occur in the following conditions:[3]
- Acute infections
- Bacteria - Staphyloccoci, Streptococci, Meningococci
- Virus- Varicella, Herpes zoster
- Fungi- Candida, Coccidioides
- Non-infectious inflammation
- Rheumatic fever
- Acute glomerulonephritis
- Collagen-Vascular diseases
- Diabetic ketoacidosis
Epidemiology and Demographics
- The incidence of the Coronavirus Disease 2019 (COVID-19) as of June 28, 2020 is approximately 9,843,073 cases worldwide with 495,760 deaths.[4]
- Patients of all age groups may develop COVID-19. However, the elderly population and immunocompromised individuals are more likely to develop severe cases of COVID-19.
Risk Factors
People of any age with certain underlying medical conditions are at increased risk for severe illness from COVID-19. These medical conditions include:[5]
- Chronic kidney disease
- Chronic obstructive pulmonary disease
- Immunocompromised state (weakened immune system) from solid organ transplant
- Obesity (body mass index [BMI] of 30 or higher)
- Serious heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies
- Sickle cell disease
- Type 2 diabetes mellitus
Screening
- A high Neutrophil-to-lymphocyte ratio has been linked to ICU admission. A routine Complete blood count (CBC) test should be done in COVID-19 patients for early detection.
Natural History, Complications, and Prognosis
- Common hematologic complications of coronavirus include lymphopenia, neutrophilia and thrombocytosis.
- Although the pathogenesis of the cytokine storm associated with Neutrophilia in COVID-19 patients is unclear. It has however been associated with poor outcomes in patients. The neutrophil-to-lymphocyte ratio has been identified as an independent risk factor for severe disease in COVID-19 patients.[6]
Diagnosis
Diagnostic study of Choice
- Peripheral white blood cell count on a CBC with differential test[3]
- Neutrophil-lymphocyte ratio
- C-reactive protein
- Erythrocyte sedimentation rate
History and Symptoms
Neutrophilia as a result of COVID-19 can present with different symptoms. People with COVID-19 have had a wide range of symptoms reported – ranging from mild symptoms to severe illness. Symptoms may appear 2-14 days after exposure to the virus. People with these symptoms may have COVID-19:[7]
- Fever or chills
- Cough
- Shortness of breath or difficulty breathing
- Fatigue
- Muscle or body aches
- Headache
- New loss of taste or smell
- Sore throat
- Congestion or runny nose
- Nausea or vomiting
- Diarrhea
Physical Examination
- There are no physical findings associated with neutrophilia.
Laboratory findings
Neutrophilia as an indicator for severe disease
- Recent studies have shown the association of a high Neutrophil-to-lymphocyte ratio (NLR) to severe forms of COVID-19 disease.
- NLR >4 on admission has been linked to ICU admission.
- COVID-19 patients with severe disease presentation had a higher NLR on admission compared to patients with a milder COVID-19 disease presentation.[8]
=Electrocardiogram
There are no ECG findings associated with COVID-19 associated neutrophilia
X-ray
There are no X-ray findings associated with COVID-19 associated neutrophilia.
Echocardiography or Ultrasound
There are no echocardiography or ultrasound findings associated with COVID-19 associated neutrophilia.
CT Scan
There are no CT scan findings associated with COVID-19 associated neutrophilia.
MRI
There are no MRI findings associated with COVID-19 associated neutrophilia.
Other imaging findings
There are no other imaging findings associated with COVID-19 associated neutrophilia.
Other Diagnostic studies
- Bone marrow biopsy, although not recommended may be helpful if there is suspicion of other disorders that can cause neutrophilia , but there is not enough evidence to support bone marrow biopsy in COVID-19 patients.
Treatment
Medical therapy
Immune-Based Therapy:
- There are insufficient data to recommend either for or against the use of COVID-19 convalescent plasma or SARS-CoV-2 immune globulins for the treatment of COVID-19.
The COVID-19 Treatment Guidelines Panel (the Panel) recommends against the use of non-SARS-CoV-2-specific intravenous immune globulin (IVIG) for the treatment of COVID-19, except in the context of a clinical trial. This should not preclude the use of IVIG when it is otherwise indicated for the treatment of complications that arise during the course of COVID-19.[9]
- There are insufficient data to recommend either for or against the use of the following agents for the treatment of COVID-19:
- Interleukin-1 inhibitors (e.g., anakinra)
- Interleukin-6 inhibitors (e.g., sarilumab, siltuximab, tocilizumab)
Except in the context of a clinical trial, the Panel recommends against the use of other immunomodulators, such as: Interferons, because of the lack of efficacy in treatment of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) and toxicity. Janus kinase inhibitors (e.g., baricitinib), because of their broad immunosuppressive effect.[9]
References
- ↑ "WHO Western Pacific | World Health Organization".
- ↑ "Severe COVID-19 symptoms may be caused by overactive neutrophils".
- ↑ 3.0 3.1 "Neutrophilia: Overview, Causes, Development of Neutrophils".
- ↑ Egeblad, Mikala; Zuo, Yu; Weber, Andrew; Yost, Christian C.; Spicer, Jonathan D.; Schwartz, Robert E.; Salvatore, Steven; Rousseau, Simon; Renaud, Stephane; Rayes, Roni; McAllister, Florencia; Looney, Mark R.; Loda, Massimo; Knight, Jason S.; Huynh, Caroline; Guerci, Philippe; Daßler-Plenker, Juliane; Crawford, James M.; Cools-Lartigue, Jonathan; Borczuk, Alain; Baxter-Stoltzfus, Amelia; Adrover, Jose M.; Barnes, Betsy J. (2020). "Targeting potential drivers of COVID-19: Neutrophil extracellular traps". Journal of Experimental Medicine. 217 (6). doi:10.1084/jem.20200652. ISSN 0022-1007.
- ↑ Ciccullo, Arturo; Borghetti, Alberto; Zileri Dal Verme, Lorenzo; Tosoni, Alberto; Lombardi, Francesca; Garcovich, Matteo; Biscetti, Federico; Montalto, Massimo; Cauda, Roberto; Di Giambenedetto, Simona (2020). "Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line". International Journal of Antimicrobial Agents: 106017. doi:10.1016/j.ijantimicag.2020.106017. ISSN 0924-8579.